Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China
Cancer Control · 2025
DOI: 10.1177/10732748251347572 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Control, 2025. Verfasst von Chang Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Oncology, The First Medical Center, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Mutation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
HER2-mutated non-small lung cancer (NSCLC) in China represents a substantial patient population characterized by an unfavorable prognosis. However, at present, the main clinical treatment options are relatively limited. HER2 mutations in Chinese NSCLC (2019-2024) demonstrated 3.8%-5.6% prevalence via NGS, exceeding global baselines, with superior detection vs PCR (4.5% vs 3.1%). In addition, more attention was paid to molecular analysis and the detection rate of HER2 genomic alterations in NSCLC patients in eastern and northern China compared to other parts of China, which might be related to regional economic differences and geographic differences in lung cancer epidemiology. The evolving therapeutic landscape has established new-generation TKIs (pyrotinib) and antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (T-Dxd) as targeted strategies for HER2-mutant NSCLC. Despite late research initiation, China rapidly advanced from retrospective analyses to pioneering new drug trials. In general, the incidence of HER2-mutated NSCLC in the Chinese population seems to be higher than the world average, and there is a large number of missed HER2-mutated NSCLC patients in China. In this field, ADCs and novel TKIs are being developed and researched in spurts, and new drugs are moving from back-line therapy to front-line therapy, and from single-drug regimens to combination regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Senior Department of Oncology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.
- Chinese PLA Key Laboratory of Oncology, Key Laboratory for Tumor Targeting Therapy and Antibody Drugs, Ministry of Education, Beijing, China.
- School of Medicine, Nankai University, Tianjin, China.
- Medical School of Chinese PLA, Beijing, China.
- Department of Stomatology, The First Medical Center of PLA General Hospital, Beijing, China.
- Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Jilin, China.
ORCID-Profile: Tao Li
Zitieren
APA
Liu, C., Li, T., Cui, X., Lv, Y., Liu, M., Zhou, X., Yang, F., Dong, Y., Li, R., Zhang, F., Zhang, T., & Hu, Y. (2025). Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China. Cancer Control. https://doi.org/10.1177/10732748251347572
Vancouver
Liu C, Li T, Cui X, Lv Y, Liu M, Zhou X, et al. Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China. Cancer Control. 2025. doi:10.1177/10732748251347572
BibTeX
@article{Liu2025,
author = {Liu, Chang and Li, Tao and Cui, Xiaoran and Lv, Yahui and Liu, Min and Zhou, Xin and Yang, Fan and Dong, Yi and Li, Ruixin and Zhang, Fan and Zhang, Tong and Hu, Yi},
title = {Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China},
journal = {Cancer Control},
year = {2025},
doi = {10.1177/10732748251347572}
}
EUVIMED